new glp 1 drug GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness GLP-1 Drugs | Association of

Early-phase results have been encouraging, with participants reporting fewer heavy drinking days and reduced cravings

10 Similarly, another systematic review and meta-analysis of 764 randomised controlled trials also showed a reduction in all-cause mortality with use of GLP-1RAs (odds ratio [OR] 0.88

The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis

The impact of the glucagon-like peptide 1 receptor agonist liraglutide on the streptozotocin-induced diabetic mouse kidney proteome

Within participants with pre-existing SUDs, initiation of a GLP-1 receptor agonist was associated with reduced risk of SUD related emergency department visits (hazard ratio 0.69 (95% CI 0.61 to 0.78), NRD 8.92 (95% CI 11.59 to 6.25)), SUD related hospital admission (0.74 (0.65 to 0.85), NRD 6.23 (8.73 to 3.74)), and SUD related mortality (0.50 (0.32 to 0.79), NRD 1.52 (2.32 to 0.72)), and associated with reduced risk of the composite endpoint of the three outcomes (0.71 (0.65 to 0.79), NRD 11.79 (14.98 to 8.60)) (fig 6 and supplementary table S11)